
    
      Eligible patients will be treated with pembrolizumab on day 1 of every 21 day cycle, given at
      a dose of 200 mg. Mifepristone 300mg PO will be administered daily starting the week prior to
      pembrolizumab. Enrollment will be paused after the first 10 patients are enrolled in the
      study for a safety evaluation. Once safety is confirmed, dose expansion cohorts will be
      performed in parallel for each indication

        -  Hormone receptor positive, hormone refractory advanced breast cancer (n = 25-34)

        -  Triple-negative advanced breast cancer (n = 27-40) Mandatory pre- and on-treatment tumor
           biopsies will be obtained in order to evaluate immunological changes in these tissues.

      Cycle length is 21 days. Patients will be evaluated every 3 cycles until progression of
      disease unless the patient is otherwise withdrawn from the study.
    
  